» Articles » PMID: 31593013

Risk Factors Associated With Progression Toward Endocrine Insufficiency in Chronic Pancreatitis

Abstract

Objective: Little data exist describing the change over time in islet function and glycemic control in patients with chronic pancreatitis (CP).

Methods: In 325 CP patients who underwent 2 mixed meal tolerance tests and/or glycated hemoglobin (HbA1c) levels, we estimated the rate of change in metabolic measures per 6 months and assessed the association between potential risk factors for diabetes and rate of change using multivariate regression models.

Results: Per 6-month time, HbA1c increased by 0.062% with a standard error of 0.029% (P = 0.037) and the ratio (area under the curve (AUC) C-peptide to AUC glucose from mixed meal tolerance testing) decreased by 0.0028 with a standard error of 0.0011 (P = 0.014). We observed more rapid decline in smokers (AUC C-peptide, P = 0.043) and patients with surgical drainage (AUC glucose, P = 0.001; ratio, P = 0.03) or with calcific pancreatitis (HbA1c, P = 0.003). In multivariate models, AUC C-peptide and ratio declined at a greater rate in smokers and HbA1c in those with pancreatic calcifications (both P < 0.05).

Conclusions: We observed a measurable decline in β-cell function and glycemic control in patients with CP. Patients with a history of tobacco smoking, surgical drainage, or pancreatic calcification may be at highest risk.

Citing Articles

Risk Factors and Mechanisms for Diabetes in Pancreatitis.

Parra Villasmil M, Bellin M Gastroenterol Clin North Am. 2025; 54(1):175-188.

PMID: 39880526 PMC: 11780253. DOI: 10.1016/j.gtc.2024.08.002.


Development of a Clinical Prediction Model for Diabetes in Chronic Pancreatitis: The PREDICT3c Study.

Jeon C, Hart P, Li L, Yang Y, Chang E, Bellin M Diabetes Care. 2022; 46(1):46-55.

PMID: 36382801 PMC: 9797648. DOI: 10.2337/dc22-1414.


Post-pancreatitis diabetes mellitus: insight on optimal management with nutrition and lifestyle approaches.

Singh A, Aggarwal M, Garg R, Stevens T, Chahal P Ann Med. 2022; 54(1):1776-1786.

PMID: 35786076 PMC: 9254994. DOI: 10.1080/07853890.2022.2090601.


Islet cell dysfunction in patients with chronic pancreatitis.

Roy A, Sahoo J, Kamalanathan S, Naik D, Mohan P, Pottakkat B World J Diabetes. 2020; 11(7):280-292.

PMID: 32843931 PMC: 7415230. DOI: 10.4239/wjd.v11.i7.280.

References
1.
Knop F, Vilsboll T, Hojberg P, Larsen S, Madsbad S, Holst J . The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regul Pept. 2007; 144(1-3):123-30. DOI: 10.1016/j.regpep.2007.07.002. View

2.
Ewald N, Kaufmann C, Raspe A, Kloer H, Bretzel R, Hardt P . Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2011; 28(4):338-42. DOI: 10.1002/dmrr.2260. View

3.
Knop F . Incretin hormones and beta cell function in chronic pancreatitis. Dan Med Bull. 2010; 57(7):B4163. View

4.
Ni Q, Yun L, Roy M, Shang D . Advances in surgical treatment of chronic pancreatitis. World J Surg Oncol. 2015; 13:34. PMC: 4326204. DOI: 10.1186/s12957-014-0430-4. View

5.
Schrader H, Menge B, Zeidler C, Ritter P, Tannapfel A, Uhl W . Determinants of glucose control in patients with chronic pancreatitis. Diabetologia. 2010; 53(6):1062-9. DOI: 10.1007/s00125-010-1705-0. View